Morepen Laboratories Ltd reported consolidated income from operations of ₹4.12 billion and net profit of ₹408.7 million for the September quarter. The company’s strong performance was driven by growth in pharmaceuticals, medical devices, and exports, supported by disciplined cost management and expanding product demand across domestic and international markets.
Morepen Laboratories Ltd, a leading player in pharmaceuticals and medical devices, has announced its Q2 FY2026 results, posting consolidated income from operations of ₹4.12 billion and a net profit of ₹408.7 million. The company’s diversified portfolio across APIs (Active Pharmaceutical Ingredients), branded formulations, and medical devices continues to deliver robust growth.
The quarter saw steady demand in domestic markets, alongside export growth in Europe and Asia, particularly in APIs and diagnostic devices. Morepen’s medical devices segment, including glucometers and test strips, maintained strong momentum, supported by rising health awareness and expanding installed base.
Management emphasized its focus on innovation, capacity expansion, and global partnerships to sustain growth. The company remains optimistic about H2 FY2026, citing strong demand visibility and favorable regulatory tailwinds.
Key Highlights
-
Income from Operations: ₹4.12 billion
-
Net Profit: ₹408.7 million
-
Growth Drivers: Pharmaceuticals, medical devices, export expansion
-
Strategic Focus: Innovation, capacity expansion, global partnerships
-
Outlook: Positive momentum expected with strong demand and regulatory support
Morepen Laboratories’ Q2 results highlight its resilience and strategic clarity in India’s evolving healthcare and pharmaceutical landscape.
Sources: LiveMint, Yahoo Finance, Morepen Laboratories Investor Centre